Mersana Therapeutics (MRSN) News Today $0.60 -0.01 (-1.69%) As of 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period What is William Blair's Estimate for MRSN FY2024 Earnings?Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities researchers at William Blair issued their FY2024 earnings per share (EPS) estimates for Mersana Therapeutics in a report released on Wednesday, February 5th. William Blair analyst A. Hsieh forecasts that the company will post earniFebruary 10, 2025 | marketbeat.comMersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comWilliam Blair starts Mersana stock with Outperform ratingFebruary 6, 2025 | msn.comWilliam Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFebruary 6, 2025 | msn.comMersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at William BlairWilliam Blair assumed coverage on Mersana Therapeutics in a report on Thursday. They set an "outperform" rating for the company.February 6, 2025 | marketbeat.comMersana Therapeutics initiated with an Outperform at William BlairFebruary 6, 2025 | markets.businessinsider.comMersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comBrokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $5.57Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, five have issueJanuary 25, 2025 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, five have given a buy recommenJanuary 22, 2025 | marketbeat.comMRSN stock touches 52-week low at $0.56 amid market challengesJanuary 21, 2025 | msn.comMersana Therapeutics CEO sells $2,618 in stockJanuary 18, 2025 | msn.comMersana Therapeutics chief development officer sells shares worth $3,444January 18, 2025 | msn.comMersana Therapeutics' chief accounting officer sells shares worth $2,061January 17, 2025 | msn.comMersana Therapeutics officer Timothy Lowinger sells $4,667 in stockJanuary 17, 2025 | msn.comMersana Therapeutics' chief legal officer sells $599 in stockJanuary 16, 2025 | msn.comMersana therapeutics VP Mandelia sells $1,128 in stockJanuary 16, 2025 | msn.comBTIG Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)January 12, 2025 | markets.businessinsider.comBuy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price VolatilityJanuary 11, 2025 | markets.businessinsider.comMersana Therapeutics selloff on data overdone, says BTIGJanuary 11, 2025 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Stock, Insider Trading ActivityJanuary 11, 2025 | benzinga.comMersana Therapeutics (NASDAQ:MRSN) Stock Quotes, Forecast and News SummaryJanuary 11, 2025 | benzinga.comWedbush Reaffirms Outperform Rating for Mersana Therapeutics (NASDAQ:MRSN)Wedbush restated an "outperform" rating and set a $4.00 target price (down previously from $7.00) on shares of Mersana Therapeutics in a research report on Friday.January 10, 2025 | marketbeat.comMersana Therapeutics, Inc.: Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | finanznachrichten.deMersana Therapeutics: Promising Clinical Data and Strong Financial Position Justify Buy RatingJanuary 10, 2025 | markets.businessinsider.comMersana falls after early-stage trial data for lead cancer therapyJanuary 10, 2025 | msn.comWhy Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?January 10, 2025 | finance.yahoo.comMersana Shares Rise on Advances With Breast-Cancer TreatmentJanuary 10, 2025 | marketwatch.comMersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | markets.businessinsider.comMersana Therapeutics: FDA Grants Additional Fast Track Designation To XMT-1660January 10, 2025 | markets.businessinsider.comMersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10, 2025 | globenewswire.comMersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast CancerJanuary 10, 2025 | globenewswire.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of "Moderate Buy" from BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have issued a buy ratDecember 28, 2024 | marketbeat.comMersana Therapeutics: We're About To Find Out If ADC Platform Is More TolerableDecember 19, 2024 | seekingalpha.comPromising Clinical Data and Valuation Support Mersana Therapeutics’ Buy RecommendationDecember 17, 2024 | markets.businessinsider.comXTX Topco Ltd Buys 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)XTX Topco Ltd raised its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 186.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 347,255 shares of the company'sDecember 13, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. increased its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 104.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 993,046 shareDecember 8, 2024 | marketbeat.comAtom Investors LP Sells 340,774 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)Atom Investors LP lessened its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 93.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,661 shares of the compaDecember 6, 2024 | marketbeat.comVerition Fund Management LLC Buys 1,292,200 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)Verition Fund Management LLC lifted its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 11,695.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,303,249 shares of the company's stock after acqDecember 6, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has earned an average rating of "Moderate Buy" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued aDecember 3, 2024 | marketbeat.comAcuta Capital Partners LLC Has $2.27 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)Acuta Capital Partners LLC cut its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 27.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,200,000 shares of the companyNovember 28, 2024 | marketbeat.comLeerink Partnrs Issues Optimistic Estimate for MRSN EarningsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for Mersana Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.5November 18, 2024 | marketbeat.comWedbush Predicts Stronger Earnings for Mersana TherapeuticsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Analysts at Wedbush increased their FY2024 earnings estimates for Mersana Therapeutics in a report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.66) per share forNovember 18, 2024 | marketbeat.comBuy Rating for Mersana Therapeutics: Anticipated XMT-1660 Data as Key CatalystNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics transferred with Buy rating at CitiNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Coverage Initiated by Analysts at CitigroupCitigroup began coverage on shares of Mersana Therapeutics in a research note on Friday. They issued a "buy" rating and a $5.00 price objective on the stock.November 15, 2024 | marketbeat.comMersana Therapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)November 15, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deMersana Therapeutics Shares Climb 23% After 3Q Results Beat EstimatesNovember 13, 2024 | marketwatch.com Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Media Mentions By Week MRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRSN News Sentiment▼0.590.39▲Average Medical News Sentiment MRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRSN Articles This Week▼52▲MRSN Articles Average Week Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MBX News Today CYRX News Today CRVS News Today PRME News Today MNPR News Today TRVI News Today ATYR News Today ALLO News Today CMPS News Today KRRO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRSN) was last updated on 2/14/2025 by MarketBeat.com Staff From Our Partners*Breaking News!* This Pharma NASDAQ Company and the U.S Army!!! This Little Known NASDAQ Company just released positive results from its drugs that have been undergoing testi...Trading Wire | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s #1 investment during Trump’s termWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.